Introduction
The sustained activation of the classical mitogen-activated protein (MAP) kinase cascade is believed to play a critical role in inducing the proliferation of some cells and the differentiation of others [l] . In this pathway, growth factors trigger the dimerisation and activation of their receptors leading to transphosphorylation of the receptors at several tyrosine residues [Z] . These phosphotyrosines then interact with proteins containing SH2 domains, two of which are the 'adaptors' Grb2 and She [3--S] . Grb2 is complexed to the guanine nucleotide exchange factor mSos that activates Ras [6, 7] . Thus the binding of Grb2 to phosphorylated receptors (and/or to the tyrosine phosphorylated form of She, which is bound to these receptors) recruits mSos from the cytosol to the plasma membrane where it converts Ras from the inactive GDP-bound form to the active GTP-bound state [8] .
Ras is associated with the plasma membrane by virtue of lipid modifications at its carboxyl terminus and its membrane localisation is essential for activation by growth factors [9] . GTP-Ras interacts with the protein kinase c-Raf, localising the latter to the plasma membrane [lo-121 where it becomes activated by a mechanism(s) that is not yet fully understood [13] . The activation of c-Raf is then thought to induce the sequential activation of MAP kinase kinase-1 (MKKl) and (Figure 2a) , which contains 0.1 mM ATP. The IC5, decreased to 0.01 l.tM at 0.025 mM ATP and increased to 0.9 pM at 2.5 mM ATP (data not shown) indicating that ZM 336372 is a competitive inhibitor with respect to ATP. The compound inhibited c-Raf tenfold more potently than B-Raf ( Figure Za ) and did not inhibit 17 of 19 other protein kinases tested, even at 50 pM (Table 1 ). The two exceptions were SAPK2alp38a and SAPKZb/p3@2 (Table l) , both of which were inhibited by ZM 336372 with an IC,, of 2 PM under the assay conditions used. The effect of ZM 336372 on SAPKZalp38a and SAPKZb/p3@2 activity is detailed at the end of the Results section.
In the experiments shown in Figure 2a (Table 2) . Moreover, unlike PD 98059, ZM 336372 was similarly unable to affect proliferation of untransformed NIH3T3 cells that had been stimulated by various mitogens (Table 3) .
Paradoxical activation of c-Raf by ZM 336372 in mammalian cells
In order to investigate why ZM 336372 did not prevent the activation of MKKl or ~42 MAPK, we exposed Swiss 3T3 cells to ZM 336372 and then measured c-Raf activity in the absence of ZM 336372 after its immunoprecipitation from the cell lysates. These experiments revealed that exposure to ZM 336372 induced a remarkable activation of c-Raf that increased several hundredfold after 60 min and was sustained for at least 3 h ( Figure Sa) . The activation was much higher than that attained after stimulation with EGF ( Figure . The activation of c-Raf by growth factors, such as EGF, is dependent on the activation of Ras. In unstimulated wiss 3T3 cells the percentage of GTP-Ras relative to GDP-Ras + GTP-Ras was 10.7 + 2.6%, which increased to 44 * 2.4% after stimulation for 2 min with EGF ( Figure 7) . After incubation for 60 min with ZM 336372 (at which time c-Raf activation is maximal; Figure Sa) , however, the proportion of GTP-Ras had not increased at all (9.5 * 1.8%) (Figure 7) . Thus the activation of c-Raf by ZM 336372 does not result from an increase in the GTPloading of Ras. In addition, pretreatment of Swiss 3T3 cells for 120 min with ZM 336372, followed by washout of the compound as described in the legend to Figure Sb 
Effect of PD 98059, wortmannin and Ro 318220 on the activation of c-Raf by ZM 336372. Lack of effect of ZM 338372 on the GTP-loading of Ras in Swiss 3T3 cells. Cells were labelled as described in the Materials and methods section before stimulation with 100 nglml EGF (2 min) or 10 uM ZM 336372 (60 min). Ras was immunoprecipitated from the cell lysates and the bound guanine nucleotides eluted and separated using thin-layer chromatography.
The figure shows an autoradiograph of a representative experiment. The quantitation of these experiments is presented in the text.
Mechanism of inhibition of c-Raf and SAPK2/p38 by ZM 336372
The finding that ZM 336372 inhibits SAPKZalp38a and the closely related homologue SAPKZb/p3@2 (collectively termed SAPKZ/p38), as well as Raf (Table l) , was intriguing, because we have reported that SB 203580 (a relatively specific inhibitor of SAPKZ/p38) also inhibits c-Raf [27] . Although the structures of ZM 336372 (Figure 1 ) and SB 203580 are completely different, these observations raised the possibility that the binding sites for ZM 336372 and SB 203580 were identical or at least overlapping.
A residue that is critical for the interaction of SB 203580 with SAPKZalp38a is Thr106, because the 4-fluorophenyl ring of this drug cannot be accommodated if a sidechain larger than threonine is present at this position. Thus we [28] and others [29, 30] have shown that SAPKZ/p38 becomes insensitive to SB 203580 if Thr106 is mutated to a residue with a more bulky sidechain, such as methionine or glutamine. The mutation of Thrl06+Met also abolished sensitivity of SAPKZalp38a or SAPKZb/p38PZ to ZM 336372 (Figure 8a,b) .
Other MAP kinase family members are insensitive to SB 203580 because the position equivalent to ThrlO6 of SAPKZalp38a is occupied by methionine or glutamine, but these enzymes can be made sensitive to SB 203580 by mutating this residue to threonine [28, 30, 31] . The results presented in Figure 8c ,d showed that two other MAP kinase family members, SAPK3 and SAPK4, could In the case of SB 203580, MAP kinases can be made even more sensitive to the drug by substituting even smaller residues, such as serine, alanine and glycine [28] . In contrast, however, mutation to these residues made SAPKZ/p38, SAPK3 and SAPK4 less sensitive to ZM 336372 than mutation to threonine ( Figure 8 , Table 4 ).
Discussion
In this paper we have identified a potent and specific inhibitor of c-Raf (ZM 336372) that shows a tenfold selectivity over B-Raf ( Figure Za) , a 30-fold selectivity over SAPKZ/p38 and does not inhibit 17 other protein kinases tested (Table 1) . Paradoxically, however, incubation of cells with ZM 336372 induces a huge activation of c-Raf (measured in the absence of this drug) that, in 3T3 cells, is twice as great as that induced by the most potent agonist described previously (EGF). The simplest interpretation of this result is that cells have a feedback loop by which Raf suppresses its own activation, so that any inhibition of Raf is rapidly counterbalanced by its reactivation. This explanation is supported by the observation that ZM 336372 does not by itself induce the activation of MKKl or p42 MAPK, yet removing it causes an activation of MKKl and p42 MAPK ( Figure Sb) . This implies that the cell does indeed contain high specific activity c-Raf that is prevented from activating its downstream substrate MKKl because of the presence of the inhibitor. The molecular mechanism by which this feedback loop operates appears to be novel, because it is not affected by inhibitors of protein kinase C, PtdIns 3-kinase or the MAP kinase cascade, and does not involve any change in the GTP loading of Ras. Our findings also raise the possibility that some substances reported to trigger the activation of c-Raf in cells might really be inhibitors of this enzyme. Nevertheless, it cannot yet be excluded that ZM 336372 exerts its effect on c-Raf more indirectly by activating or inhibiting another unknown target allied to c-Raf activation. 1999, Vol 6 No 6 The finding that ZM 336372 inhibits SAPK2/p38 (Table 1 ) as well as c-Raf and B-Raf was intriguing because SB 203580, a structurally unrelated compound that is a relatively specific inhibitor of SAPKZ/p38, also inhibits c-Raf [27]. Moreover, like ZM 336372, SB 203580 also induces an activation of c-Raf in cells (measured in the absence of the drug) [27] . In this paper we demonstrate that the binding sites for ZM 336372 and SB 203580 on SAPK2lp38 (and presumably c-Raf and B-Raf) are likely to overlap because the single mutation of ThrlOb+Met abolishes inhibition by both compounds (Figure 8 ). A-Raf should also be sensitive to ZM 336372 because the critical threonine residue is also conserved in this isoform. In addition, other MAP kinase family members that are resistant to SB 203580 because they possess methionine instead of threonine at this position, can be made sensitive to either ZM 336372 or SB 203580 by changing this residue to threonine ( Figure  8 ). Mutation to smaller residues (glycine and alanine), however, increases sensitivity to SB 203580, but decreases sensitivity to ZM 336372 (Table 4) . We have excluded the possibility that SB 203580 triggers the activation of c-Raf by binding to SAPK2/p38 rather than c-Raf itself, because the concentration of SB 203580 required to activate c-Raf in cells is higher than that required to inhibit SAPK2/p38.
In addition, SB 203580 still induces the activation of c-Raf in cells overexpressing an SB-203580-resistant mutant of SAPK2/p38 in which SB 203580 no longer prevents the activation of MAPKAP-KZ (a downstream target of SAPK2/p38) [27] . It could also be argued that the activation of c-Raf by ZM 336372 is mediated by the binding of this drug to SAPK2/p38
and not c-Raf itself. This is unlikely, however, because ZM 336372 has a much greater effect on the activation of c-Raf than SB 203580 does, an observation that correlates with its greater potency against the isolated c-Raf enzyme rather than its somewhat lower potency against SAPK2/p38.
Preincubation
of cells with ZM 336372 does not trigger any activation of p42 MAPK (Figure 3 ), yet subsequent exposure to EGF in the continued presence of ZM 336372, which only increases c-Raf activity by a further ZO-30%, induces essentially complete activation of p42 MAPK ( Figure  3) 
